Copanlisib
Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Wikipage redirect
primaryTopic
Copanlisib
Copanlisib (BAY 80-6946), developed by Bayer, is a selective Class I phosphoinositide 3-kinase inhibitor which has shown promise in Phase I/II clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
has abstract
Copanlisib (BAY 80-6946), deve ...... chronic lymphocytic leukemia.
@en
IUPAC name
2-Amino-N-[7-methoxy-8-(3-morp ...... -5-yl]pyrimidine-5-carboxamide
@en
thumbnail
Wikipage page ID
45,570,623
Wikipage revision ID
693,047,217
othernames
hypernym
comment
Copanlisib (BAY 80-6946), deve ...... chronic lymphocytic leukemia.
@en
label
Copanlisib
@en
wasDerivedFrom
isPrimaryTopicOf
name
Copanlisib
@en